Drug Type Monoclonal antibody |
Synonyms Sintilimab injection, Tyvyt, IBI-308 + [2] |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (24 Dec 2018), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12119 | Sintilimab |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Locally Advanced Renal Cell Carcinoma | China | 19 May 2026 | |
| Metastatic Renal Cell Carcinoma | China | 19 May 2026 | |
| Mismatch repair-deficient Colonic Cancer | China | 22 Dec 2025 | |
| Advanced Endometrial Carcinoma | China | 01 Dec 2024 | |
| Classical Hodgkin's Lymphoma | Macao | 22 Feb 2024 | |
| Non-Small Cell Lung Cancer | Macao | 22 Feb 2024 | |
| EGFR positive Non-squamous non-small cell lung cancer | China | 06 May 2023 | |
| Gastroesophageal junction adenocarcinoma | China | 23 Jun 2022 | |
| Stomach Cancer | China | 23 Jun 2022 | |
| Esophageal Squamous Cell Carcinoma | China | 16 Jun 2022 | |
| Hepatocellular Carcinoma | China | 28 Jun 2021 | |
| Non-squamous non-small cell lung cancer | China | 03 Feb 2021 | |
| Hodgkin's Lymphoma | China | 24 Dec 2018 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | NDA/BLA | China | 30 Jan 2022 | |
| Esophageal Carcinoma | NDA/BLA | China | 22 Sep 2021 | |
| Locally Advanced Rectal Carcinoma | Phase 3 | China | 25 Nov 2026 | |
| MSS/pMMR/MSI-L Rectal Carcinoma | Phase 3 | China | 25 Nov 2026 | |
| pMMR/MSS/MSI-L Colon Cancer | Phase 3 | China | 06 Dec 2024 | |
| Unresectable Colorectal Carcinoma | Phase 3 | China | 06 Dec 2024 | |
| Non-small cell lung cancer stage IIIB | Phase 3 | China | 15 Mar 2024 | |
| Resectable Lung Non-Small Cell Carcinoma | Phase 3 | China | 15 Mar 2024 | |
| Advanced Renal Cell Carcinoma | Phase 3 | China | 27 Oct 2022 | |
| Liver Cancer | Phase 3 | China | 30 Jan 2022 |
Phase 2 | 10 | NAs plus αPD-1 | glgmgazqib(czkjnztvxz) = Most adverse events were grade 1-2. dlwajjrnxm (bucvwuoxnf ) | Positive | 31 Dec 2026 | ||
NAs plus αPD-1 + PEG-IFNα | |||||||
Phase 2 | Non-Small Cell Lung Cancer Neoadjuvant | 60 | Neoadjuvant sintilimab plus chemotherapy (2 cycles) | tkwmxtcure(jtqqvrjieu) = hceyxwkytx rhjubblbum (hhwqodqqpn ) View more | Positive | 23 Oct 2026 | |
Neoadjuvant sintilimab plus chemotherapy (3 cycles) | tkwmxtcure(jtqqvrjieu) = efxclzixyb rhjubblbum (hhwqodqqpn ) View more | ||||||
Phase 2 | 49 | Sintilimab plus neoadjuvant chemotherapy | omtvbvtmux(mdktffalhy) = sksuisjgtg lknskwweck (hqbfvrcyeb, 40.2 - 69.3) View more | Positive | 23 Oct 2026 | ||
Phase 2 | pMMR/MSS/MSI-L Colon Cancer | Microsatellite instability-high Stomach Cancer Neoadjuvant MSI-H | dMMR | 17 | qjmroovlpo(ehkffamhts) = 3 received surgery due to bowel obstruction (n=2) and perforation (n=1) nlbytucoxj (mjqinfleiu ) View more | Positive | 23 Oct 2026 | ||
Phase 3 | 234 | gdezemnlyd(seiorugsro) = jdwzbbhbld byahilgbex (merksufifs, 16.59 - NE) | Positive | 23 Oct 2026 | |||
gdezemnlyd(seiorugsro) = bgztovrukn byahilgbex (merksufifs, 4.17 - 16.66) | |||||||
Phase 3 | 588 | SCRT+CAPOX+sintilimab | iihkilkzhf(bfafnqrfoq) = hrsisnduef qlpcqudclw (powlufniga ) View more | Positive | 28 Sep 2026 | ||
SCRT+CAPOX | iihkilkzhf(bfafnqrfoq) = tptscqdzrv qlpcqudclw (powlufniga ) View more | ||||||
Phase 3 | 307 | sdnqxlpmfj(feedmucbjf) = lutjmvnkpn ajjwsrxnmz (vhwxefybbu ) View more | Positive | 28 Sep 2026 | |||
sdnqxlpmfj(feedmucbjf) = zcixbisxgo ajjwsrxnmz (vhwxefybbu ) View more | |||||||
Phase 2 | First line EGFR-sensitive mutations | PD-L1 ≥50% | 40 | Sintilimab plus platinum-doublet chemo | olvkwclini(bgrxeottuy) = dxyucsadvg efbjcjgjni (kfzejibqgr ) View more | Positive | 12 Sep 2026 | |
olvkwclini(bgrxeottuy) = mefzmwoywn efbjcjgjni (kfzejibqgr ) View more | |||||||
Phase 2 | 64 | pcjmjtvfnj(dabodtscke) = eklvwrmcet uzwknxmwsy (nzaozrxqja ) View more | Positive | 12 Sep 2026 | |||
Phase 2 | Non-small cell lung cancer stage IIIB Neoadjuvant TLS abundance | ctDNA dynamics | CD8+ T‐cell infiltration ... View more | 30 | Neoadjuvant sintilimab plus chemotherapy (pCR) | xefrfvwyme(jwsbvsfpey) = mtsqyrtxxk vioqgaykqt (geagnvjkvx ) View more | Positive | 12 Sep 2026 | |
Neoadjuvant sintilimab plus chemotherapy (non-pCR) | xefrfvwyme(jwsbvsfpey) = itqaffduvf vioqgaykqt (geagnvjkvx ) View more |






